Acesso livre
Acesso livre

Hematologia

Recomendações clínicas para diagnóstico e monitoramento de pacientes com cardiomiopatia amiloide transtiretina.

11 Jul, 2022 | 13:53h

Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia – Clinical Cardiology

Conteúdos relacionados:

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis – European Heart Journal

Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis – 2021 – Arquivos Brasileiros de Cardiologia

AHA Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis.

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases – European Heart Journal

Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association – Circulation

Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis – Canadian Journal of Cardiology

AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management – JACC: CardioOncology

Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis – Circulation: Heart Failure

 

Estudo randomizado | Eficácia e segurança do regime quimioterápico baseado em pegasparaginase vs. regime quimioterápico baseado em L-asparaginase para linfoma de célula T/natural killer extranodal avançado recém-diagnosticado.

11 Jul, 2022 | 13:32h

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial – JAMA Oncology (gratuito por tempo limitado)

Editorial: De-escalating Chemotherapy for Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Step Toward Improved Treatment of a Rare Virus-Associated Cancer – JAMA Oncology (gratuito por tempo limitado)

Ver também: Visual Abstract

 

Revisão | Doença falciforme.

8 Jul, 2022 | 11:28h

Sickle Cell Disease: A Review – JAMA (gratuito por tempo limitado)

Revisão clínica em áudio: Sickle Cell Disease – JAMA

 

Atualizações de 2021 sobre coagulação e transfusão.

8 Jul, 2022 | 11:09h

Coagulation and Transfusion Updates from 2021 – Journal of Cardiothoracic and Vascular Anesthesia

 

M-A | Anticoagulantes orais diretos vs. antagonistas da vitamina K em pacientes com fibrilação atrial com bioprótese de válvula cardíaca.

8 Jul, 2022 | 10:56h

An Updated Meta-Analysis of DOACs vs. VKAs in Atrial Fibrillation Patients With Bioprosthetic Heart Valve – Frontiers in Cardiovascular Medicine

 

M-A | Anticoagulantes para tromboprofilaxia em pacientes agudos internados.

6 Jul, 2022 | 11:26h

Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis – The BMJ

Estudo de coorte | Desfechos do tratamento e funções do transplante e da manutenção do rituximabe em pacientes com linfoma de células do manto não tratado previamente.

6 Jul, 2022 | 10:50h

Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts – Journal of Clinical Oncology

Comunicado de imprensa: Mantle cell lymphoma treatment varies according to setting – Weill Cornell Medicine

Casos EM | Os 7 “T” dos protocolos de hemorragia maciça.

6 Jul, 2022 | 10:44h

EM Cases: The 7 Ts of Massive Hemorrhage Protocols – emDocs

Estudo randomizado | Tomografia computadorizada vs. [18F]FDG-PET-TC para febre neutropênica persistente ou recorrente em pacientes de alto risco.

5 Jul, 2022 | 11:37h

[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial – The Lancet Haematology (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

FDA alerta sobre possível risco aumentado de morte e de sérios efeitos adversos com uso de duvelisibe.

5 Jul, 2022 | 11:21h

FDA Warns About Possible Increased Risk of Death and Serious Side Effects With Duvelisib – The ASCO Post

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.